The intersection of advanced molecular diagnostics and the Multiple Myeloma Therapy Market is creating highly precise patient segmentation strategies. Techniques like Next-Generation Sequencing (NGS) and Next-Generation Flow cytometry allow clinicians to detect Minimal Residual Disease (MRD) down to one cancer cell in a million. This incredible diagnostic precision allows oncologists to...